PMID: 9546800Apr 18, 1998Paper

Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines

AIDS Research and Human Retroviruses
B OzpolatL B Lachman

Abstract

Immunoliposomes containing monoclonal antibodies (MAbs) to the costimulatory molecules CD28 and CTLA4 and their counterreceptors B7-1 (CD80) and B7-2 (CD86) were evaluated for the ability to increase the immune response to recombinant envelope protein rgp120 of the MN strain of human immunodeficiency virus type 1 (HIV-1) during vaccination. MAbs were attached to rgp120-containing liposomes via a biotin-avidin-biotin bridge. Mice vaccinated with immunoliposomes were found to have a strong delayed-type hypersensitivity (DTH) response to the weakly immunogenic gp120 that was dependent on the presence of the MAbs. However, this vaccination protocol did not induce humoral immunity. The DTH response was not accompanied by increased production of interferon gamma (IFN-gamma) or interleukin 4 (IL-4), implying that the primary cellular interaction was between the immunoliposomes and cells of the reticuloendothelial system and not helper T (Th) cells. This strategy of incorporating antibodies to costimulatory molecules on the surface of antigen-containing particulates, such as liposomes or microspheres, can be used to increase DTH immune responses to protein or peptide vaccines.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·L A TurkaD Gordon
Dec 1, 1992·The Journal of Experimental Medicine·P S LinsleyN K Damle
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·H ReiserL M Nadler
Jan 1, 1992·Annals of the New York Academy of Sciences·T R Mosmann
Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C D GimmiL M Nadler
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P S LinsleyJ A Ledbetter
Aug 1, 1995·AIDS Research and Human Retroviruses·L B LachmanJ L Cleland
Aug 26, 1994·Science·B K FinckD Wofsy
Jun 1, 1994·Current Opinion in Immunology·J P Allison
Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·C D GimmiL M Nadler
Nov 4, 1993·Nature·M AzumaC Somoza
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
Jan 1, 1994·Annual Review of Immunology·R A Seder, W E Paul
Jun 1, 1993·Immunology Today·F Powrie, R L Coffman
Mar 22, 1996·Science·D R LeachJ P Allison
Apr 7, 1997·The Journal of Experimental Medicine·Y WuY Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.